Cancer – Breast TNBC – OncWonk – Dr Bier's Oncology Research Reviews

Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast Cancer

November 16, 2025

| Cancer - Breast, Cancer - Breast TNBC, Radiation Therapy

📝 Comment: This trial provides a critical, high-level confirmation: modern systemic therapy has fundamentally changed the risk/benefit profile of post-mastectomy chest-wall irradiation (CWI) for intermediate-risk breast cancer. The key takeaway is that for the overall population, a minimal absolute reduction in local recurrence (less than 2 percentage points) did not translate into an Overall Survival […]

Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now?

November 2, 2025

| No Comments

| Cancer - Breast TNBC, Metronomic Chemo

Comment: This 2017 article’s real contribution here isn’t the narrative review—which, as is too selective to be high-quality—but the new VICTOR-2 subgroup data. While a 35.7% Clinical Benefit Rate in an elderly (median age 69) metastatic TNBC population is certainly interesting, it’s from a tiny, single-arm cohort of 28 patients. This paper highlights metronomic chemotherapy […]

Metronomic chemotherapy for non-metastatic triple negative breast cancer: Selection is the key

November 2, 2025

| No Comments

| Cancer - Breast TNBC, Metronomic Chemo, Uncategorized

Comment: This paper tries to identify the true clinical niche for Metronomic Chemotherapy: adjuvant maintenance therapy for patients with residual disease. This is the high-risk subgroup where the gold standard, maximum tolerated dose (MTD) chemotherapy, has clearly failed to eradicate the disease. The success of the CREATE-X trial in this specific, defined population—with its remarkable […]

Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study

October 26, 2025

| No Comments

| Cancer - Breast, Cancer - Breast TNBC, Metronomic Chemo

Comment: This study presents a very practical and appealing option for managing advanced HER2-negative breast cancer in the palliative setting. The key takeaway is the dual advantage of this all-oral metronomic regimen: it demonstrates clinically relevant activity while maintaining an exceptionally low toxicity profile. However, the regimen’s main strength is its safety and convenience. Being […]